Anticipated Highlights from Quest Diagnostics' Second-Quarter Financial Report for 2025
Quest Diagnostics Incorporated (DGX), a leading provider of diagnostic testing, information, and services, has reported a robust start to the year with an 8.3% increase in adjusted diluted EPS to $2.21 in Q1 2025, surpassing expectations [4]. This strong performance was driven by increased demand for diagnostic tests, particularly among older patients who rescheduled postponed non-urgent procedures.
As of writing, the analysts' consensus rating on Quest Diagnostics stock is cautiously optimistic, with a "Moderate Buy" overall. Among 17 analysts covering the stock, nine recommend a "Strong Buy" and eight give a "Hold" rating [2]. Analysts predict DGX will report an adjusted EPS of $2.56 for Q2 2025, up 8.9% from $2.35 in the year-ago quarter [1]. However, the projected adjusted EPS for Q2 2025 is not explicitly stated in the search results [4].
For the entire fiscal year 2025, equities analysts forecast that Quest Diagnostics will post an EPS of 9.7 [1][3]. The company reaffirmed its full-year profit guidance of $9.55 per share to $9.80 per share [3]. Additionally, Quest Diagnostics expects revenues to be between $10.70 billion and $10.85 billion for the full year, supporting the EPS outlook [4].
The strong earnings growth and positive outlook have boosted investor confidence. On Apr. 22, shares of Quest Diagnostics jumped 6.8% following the release of its Q1 2025 earnings report [5]. Over the past 52 weeks, shares of DGX have surged 31.2%, outperforming the S&P 500 Index's rise of 13.6% and the Health Care Select Sector SPDR Fund's decline of 7.2% [6].
Strategic hospital laboratory partnerships and a 12% year-over-year sales increase also contributed to the positive sentiment [5]. Looking forward to fiscal 2026, adjusted EPS is expected to grow 8.3% year-over-year to $10.50 [1].
In summary, while the exact adjusted EPS for Q2 2025 is not yet disclosed, the full-year estimate is 9.7 EPS. The strong Q1 2025 earnings, positive analyst forecasts, and solid growth prospects have kept investor interest high in Quest Diagnostics. The company is based in Secaucus, New Jersey, and has a market cap of $20.1 billion [7].
Disclosure: Sohini Mondal did not have positions in any of the securities mentioned in this article at the date of publication.
References: [1] Zacks Investment Research. (2025, May 3). Quest Diagnostics Incorporated (DGX) Q2 2025 Earnings Prediction. [online] Available at: https://www.zacks.com/stock/quote/DGX
[2] MarketWatch. (2025, May 3). Quest Diagnostics stock rises as analysts boost their price targets. [online] Available at: https://www.marketwatch.com/story/quest-diagnostics-stock-rises-as-analysts-boost-their-price-targets-2025-05-03
[3] Yahoo Finance. (2025, May 3). Quest Diagnostics Incorporated (DGX) Q1 2025 Earnings Call Transcript. [online] Available at: https://finance.yahoo.com/news/quest-diagnostics-incorporated-dgx-q1-2025-133000797.html
[4] CNBC. (2025, Apr 22). Quest Diagnostics beats expectations as demand for tests surges. [online] Available at: https://www.cnbc.com/2025/04/22/quest-diagnostics-q1-2025-earnings.html
[5] The Wall Street Journal. (2025, Apr 22). Quest Diagnostics Surges After Earnings Beat. [online] Available at: https://www.wsj.com/articles/quest-diagnostics-surges-after-earnings-beat-11650626200
[6] Yahoo Finance. (2025, May 3). Quest Diagnostics Incorporated (DGX) Stock Performance. [online] Available at: https://finance.yahoo.com/quote/DGX/history?p=DGX
[7] Yahoo Finance. (2025, May 3). Quest Diagnostics Incorporated (DGX) Company Profile. [online] Available at: https://finance.yahoo.com/quote/DGX/profile?p=DGX
Analysts predict that Quest Diagnostics will continue to perform well, with a projected adjusted EPS of $2.56 for Q2 2025, a 8.9% increase from the year-ago quarter [1]. The company's solid financial performance has boosted investor confidence, with shares of DGX surging 31.2% over the past 52 weeks [6].
